Loading...
Loading...
SYRS| Name | Value |
|---|---|
| Revenues | 2.8M |
| Cost of Revenue | 0.7M |
| Gross Profit | 2.2M |
| Operating Expense | 36.8M |
| Operating I/L | -34.0M |
| Other Income/Expense | -3.1M |
| Interest Income | 2.1M |
| Pretax | -36.3M |
| Income Tax Expense | 1.3M |
| Net Income/Loss | -36.3M |
Syros Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development of treatments for cancer and monogenic diseases, with a focus on gene control medicines. The company's revenue is generated through the development and commercialization of its lead product candidates, including Tamibarotene, a selective retinoic acid receptor alpha agonist, SY-2101, a novel oral form of arsenic trioxide, and SY-5609, a cyclin-dependent kinase 7 inhibitor. Additionally, Syros has established research collaborations and option agreements with industry partners to identify therapeutic targets, further contributing to its revenue stream.
